Open Nav

Please submit your session questions in advance at

Sense Diagnostics, Inc.

Sense Diagnostics team is skilled in the clinical care of severe brain injuries, with three practicing physicians among the founders.The SENSE scanner transmits low power radio waves through the patient’s brain every few minutes. It detects scattering by the blood cells and plasma when the signal encounters a hemorrhage. This fact allows our scanner to detect bleeding in minutes, not hours. The SENSE device was invented and designed by practicing clinicians and researchers. It will fit easily into the workflow and footprint of the ambulance and the ICU. It also doesn’t interfere with other treatments or monitors used the patient.

Current funding initiatives: FDA Approval (1Q18 -2Q20): $3.5-5 million. During this phase, the company will be conducting a pivotal clinical trials on Traumatic Brain Injury and Stroke patients. Targeting preparation and submission of required documentation to the FDA by June 2019. Initiating sales, production capabilities for product launch in mid 2020.

  • Date:Tuesday, February 12
  • Time:11:15 AM - 11:30 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23611
  • Goal for Presentation:Find Investors and/or Strategic Partners
  • Company
  • Company HQ City:Cincinnati
  • Company HQ State:Ohio
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$2300000
  • Size of Last Investment Round:$1300000
  • Previous and Current Investors:Queen City Angels, Cleveland Clinic Foundation, Accelerant Fund
  • CEO/Top Company Official:Geoff Klass
  • Year Founded:2014
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:SENSE Brain Injury Scanner
  • Development Phase of Primary Product:Other/Not Applicable
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):1
Dan Kincaid
Sense Diagnostics,Inc